234 related articles for article (PubMed ID: 16960554)
21. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
22. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
23. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
[TBL] [Abstract][Full Text] [Related]
26. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression.
Grote D; Cattaneo R; Fielding AK
Cancer Res; 2003 Oct; 63(19):6463-8. PubMed ID: 14559838
[TBL] [Abstract][Full Text] [Related]
27. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
[TBL] [Abstract][Full Text] [Related]
28. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma.
Suter SE; Chein MB; von Messling V; Yip B; Cattaneo R; Vernau W; Madewell BR; London CA
Clin Cancer Res; 2005 Feb; 11(4):1579-87. PubMed ID: 15746063
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
30. Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
Lühl NC; Zirngibl F; Dorneburg C; Wei J; Dahlhaus M; Barth TF; Meyer LH; Queudeville M; Eckhoff S; Debatin KM; Beltinger C
Haematologica; 2014 Jun; 99(6):1050-61. PubMed ID: 24700491
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
33. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
34. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
35. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
36. Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells.
Awano M; Fujiyuki T; Shoji K; Amagai Y; Murakami Y; Furukawa Y; Sato H; Yoneda M; Kai C
Cancer Sci; 2016 Nov; 107(11):1647-1652. PubMed ID: 27561180
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
38. Attenuated oncolytic measles virus strains as cancer therapeutics.
Msaouel P; Iankov ID; Dispenzieri A; Galanis E
Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
[TBL] [Abstract][Full Text] [Related]
39. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]